Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

OBJECTIVE: Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer‐term (104 weeks) efficacy and safety results. METHODS: Patients with active AS were randomized to subcutaneous secukinumab 150 mg, 75 mg, or pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., Readie, A., Richards, H. B., Porter, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518281/
https://www.ncbi.nlm.nih.gov/pubmed/28235249
http://dx.doi.org/10.1002/acr.23233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518281/
https://www.ncbi.nlm.nih.gov/pubmed/28235249
http://dx.doi.org/10.1002/acr.23233

Ejemplares similares